My notes:
- 2 of 3 S1s no comments, other one had one comment - SEC wants the addition of Dawson James, so sounds like the S1s are close
- IPO road show will be ~3 days, virtual. Co saves $ and time - Joe expects 1-2 large entities to step up and take most of the shares.
- Joe believes the offering will be committed, not "best efforts"... but we'll see. If Joe has to give up 2-4% to get that deal, it's an easy decision
- Singapore deal "close" - w lawyers
- LOI w China - close, Chinese partners getting back to Joe ASAP after Harvest holiday - want the whole package (CV, swine flu, cancer), so up front would be "significantly higher" than the original $5MM for just CV
- Canada seems engaged and promising
- BK signed deal with a manufacturer, will lead to licensing payment to NGIO ($ unknown)
- Rich's update - good recap of approach w kids, etc. Moving forward on other matters in the meantime, bladder cancer
- Worked out deal with 3M on adjuvant. Working on lyophilized formula (powdered... I cheated w Google) to avoid issues of freezing for distribution and getting safely to patients that will occur with other vaccines.
- Dr EvH - emphasized the LT response of Ii-key and our safety profile
- Re-iterated no animal trials. Trial patient count in IND more like ~10k patients vs 30-50k in other trials due to safety history. FDA appears to agree on this point.
- Not sure what is pushing the SP down - warning to any party, SEC is watching. Best thing to do is plow forward w the business
- Marshall Stevens working on valuation and appraisal. $350MM previously for breast cancer only. Expect higher, particularly w BK deal signing, should only go up over the next 30 days as further deals are signed and up-front payments come in..
- NGIO shares offered to current shareholders? Joe would like to. Still working out details w Dawson James. If you want to call Joe, he can hook you up with DJ and you can speak to them directly.
- FDA agreed on most major points of IND. Should be getting to clinic "quickly".
- Joe has no more need for convertible notes as financing. Financing thru S1s and business cash flow should carry us from now forward.
That's the relevant info I was able to write down and remember thru 9:45 ET
Seemed positive and confident - from Joe on thru the scientists.
- 2 of 3 S1s no comments, other one had one comment - SEC wants the addition of Dawson James, so sounds like the S1s are close
- IPO road show will be ~3 days, virtual. Co saves $ and time - Joe expects 1-2 large entities to step up and take most of the shares.
- Joe believes the offering will be committed, not "best efforts"... but we'll see. If Joe has to give up 2-4% to get that deal, it's an easy decision
- Singapore deal "close" - w lawyers
- LOI w China - close, Chinese partners getting back to Joe ASAP after Harvest holiday - want the whole package (CV, swine flu, cancer), so up front would be "significantly higher" than the original $5MM for just CV
- Canada seems engaged and promising
- BK signed deal with a manufacturer, will lead to licensing payment to NGIO ($ unknown)
- Rich's update - good recap of approach w kids, etc. Moving forward on other matters in the meantime, bladder cancer
- Worked out deal with 3M on adjuvant. Working on lyophilized formula (powdered... I cheated w Google) to avoid issues of freezing for distribution and getting safely to patients that will occur with other vaccines.
- Dr EvH - emphasized the LT response of Ii-key and our safety profile
- Re-iterated no animal trials. Trial patient count in IND more like ~10k patients vs 30-50k in other trials due to safety history. FDA appears to agree on this point.
- Not sure what is pushing the SP down - warning to any party, SEC is watching. Best thing to do is plow forward w the business
- Marshall Stevens working on valuation and appraisal. $350MM previously for breast cancer only. Expect higher, particularly w BK deal signing, should only go up over the next 30 days as further deals are signed and up-front payments come in..
- NGIO shares offered to current shareholders? Joe would like to. Still working out details w Dawson James. If you want to call Joe, he can hook you up with DJ and you can speak to them directly.
- FDA agreed on most major points of IND. Should be getting to clinic "quickly".
- Joe has no more need for convertible notes as financing. Financing thru S1s and business cash flow should carry us from now forward.
That's the relevant info I was able to write down and remember thru 9:45 ET
Seemed positive and confident - from Joe on thru the scientists.
9
